Vitamin D acts like a hormone after activation. For longevity-focused adults, the strongest case is correcting low blood levels and holding a moderate daily vitamin D3 target—often with magnesium and diet-matched calcium—not megadosing when levels are already enough. Benefits track deficiency and daily dosing; risks cluster at extremes and yearly megadoses. (Full Review)

Protocol

Form

Cholecalciferol (D3)

Prefer D3 over D2 for raising and sustaining 25(OH)D

Typical maintenance dose

1,000–2,000 IU/day

2,000–5,000 IU/day for higher functional levels or higher body weight; individualize with labs

Standard longevity-oriented approach

~40–60 ng/mL 25(OH)D

Correct deficiency with D3, then maintain; take with a fat-containing meal

Time to effect

Blood level (25(OH)D)

6–12 weeks

Rise with steady daily or weekly dosing

Symptoms / infection risk

After status correction

Any change lags repletion of low levels

Bone density

Months to years

Structural bone change, not rapid

Benefits

High: Correction of deficiency and support of bone mineralization; reduced hip and total fracture risk when combined with calcium

Medium: Lower risk of acute respiratory infection; reduced cancer mortality with daily vitamin D3; fall risk reduction at moderate daily doses in older adults

Low: Muscle function and physical performance in deficient older adults; all-cause mortality reduction in deficient or high-risk groups

Speculative: Telomere maintenance and cellular aging markers; autoimmune disease risk modulation

Contraindications

Documented vitamin D toxicity or unexplained hypercalcemia until cause is treated

Primary hyperparathyroidism with hypercalcemia (except under specialist protocols)

Active granulomatous disease with hypercalcemia (sarcoidosis, etc.) without specialist oversight

Known severe hypersensitivity to a specific formulation's excipients

Rare idiopathic infantile hypercalcemia / CYP24A1 deficiency phenotypes (specialist only)

Key Interactions

Thiazide diuretics (hydrochlorothiazide, chlorthalidone)

Digoxin

Lithium

Orlistat, bile-acid sequestrants (cholestyramine, colesevelam), mineral oil

Anticonvulsants (phenytoin, phenobarbital, carbamazepine) and rifampin

Glucocorticoids

Calcium supplements / high-dose calcium carbonate or citrate

Vitamin K antagonists (warfarin)

Magnesium, vitamin K2, vitamin A

Aluminum-containing phosphate binders (chronic kidney disease)

Risk & Side Effects

High: Hypercalcemia and vitamin D toxicity from excess intake

Medium: Increased falls and fractures with high-dose bolus regimens; hypercalciuria and kidney stone risk

Low: Gastrointestinal discomfort and nonspecific symptoms; interaction-related harm via elevated calcium or altered drug levels

Speculative: Possible U-shaped associations at very high 25(OH)D

Monitoring

Marker	Target	Why
25-hydroxyvitamin D (25(OH)D)	~40–60 ng/mL (100–150 nmol/L)	Status marker for stores and dosing
Serum calcium (total or ionized)	Within lab reference (e.g., ~8.6–10.2 mg/dL total)	Detect hypercalcemia early
PTH (intact)	Mid-normal or appropriate for calcium status	Flags secondary hyperparathyroidism from low D or primary disease
eGFR / creatinine	Stable, age-appropriate	Kidney filter function for dosing safety
Serum magnesium	Mid-normal	Cofactor for vitamin D enzymes
24-h urinary calcium (selected)	Within lab reference	Stone risk on calcium + vitamin D regimens

Cadence: Recheck 25(OH)D after 8–12 weeks on a stable dose, then every 6–12 months once at target—or sooner after dose changes, deep winter, bariatric surgery, weight change, or new interacting drugs

Qualitative Assessment

Winter illness frequency and recovery time
Muscle comfort, proximal strength, and fall confidence in older adults
Bone-related pain pattern historically linked to osteomalacia (if previously deficient)
Absence of polyuria, severe thirst, or GI symptoms that suggest excess

Vitamin D for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment